Belite Bio Inc

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Belite Bio Inc advances oral therapy for retinal diseases

Belite Bio Inc's financials show solid cash reserves and strategic investments in research, while clinical trials progress positively with enrollment milestones and upcoming data releases.
The company's focus on safety, efficacy, and market differentiation for their oral therapeutic presents both challenges and opportunities in a competitive landscape.
Overall, Belite Bio Inc's innovative approach to treating Stargardt disease and GA shows promise, supported by regulatory designations and a clear path for future growth.

Belite Bio Inc reports revenue growth and progresses in Phase III trials

Belite Bio Inc shows positive revenue growth and financial stability but faces challenges in trial enrollment and managing expenses.
Tinlarebant's designations and progress in Phase III trials offer promising opportunities for future growth and FDA approval.
Balancing innovation with financial sustainability will be crucial for Belite Bio Inc's long-term success in the biopharmaceutical industry.

Belite Bio Inc reports Q4 loss, eyes positive trial outcomes

Belite Bio Inc's Q4 2023 performance reflects ongoing investment in research and development, with a focus on advancing treatments for retinal diseases.
The company's financial stability and upcoming milestones in 2024 position it well for future growth and progress in clinical trials.
Challenges in trial management and data handling require careful navigation, while opportunities lie in presenting key findings and exploring treatment synergies.

Belite Bio advances novel treatment for retinal diseases, financials stable

Belite Bio's Q1 2024 earnings call highlighted progress with Tinlarebant, a promising treatment for Stargardt disease and Geographic Atrophy. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth and potential market success.

Belite Bio Inc progresses in Stargardt trials, maintains strong cash position

Belite Bio Inc's Q2 2024 earnings call highlighted advancements in Tinlarebant trials, positive Phase II study results, and a robust financial position despite reporting a net loss. The company's focus on addressing Stargardt disease with Tinlarebant presents promising opportunities for future growth and market approval.

Belite Bio reports progress in clinical trials and financial stability

Belite Bio's Q3 performance reflects positive clinical and financial outcomes, positioning the company well for future growth and innovation in ocular disease treatments.
While facing challenges in patient tolerance monitoring and trial operations, Belite Bio's strengths in balance sheet stability and therapeutic efficacy offer opportunities for market success and expansion.
With strategic leadership additions and ongoing clinical advancements, Belite Bio is poised to make significant strides in addressing unmet medical needs in Stargardt disease and geographic atrophy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Biopharma Conference being held in Miami, FL, on March 11-13, 2024. The Company will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET.

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City.

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that management will participate in a fireside chat at the BTIG Ophthalmology Day on Monday, November 27, 2023, at 3:00 p.m. ET.

Belite Bio to Participate in the BTIG Ophthalmology Day

Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Kento Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Bruce Jackson - The Benchmark Company Operator Hello and thank you for joining us to discuss Belite's Third Quarter 2023 Financial Results. Joining the call is Dr. Tom Lin, Chairman and CEO, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Wan Zhang, Chief Financial Officer of BeLite Bio.

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company's financial results for the third quarter ended September 30, 2023, and provide a general business update.

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, presented final data from a 24-month, Phase 2 study of Tinlarebant in adolescent STGD1 (“LBS-008-CT02”) at the American Association of Ophthalmology (AAO) Annual Meeting.

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

SAN DIEGO, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs, today announced that the two-year data from the Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent STGD1 will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2023) being held November 3 – November 6, 2023, in San Francisco, CA.

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Only a small percentage of recently listed biotech and healthcare companies have posted share price gains in the past year, highlighting the risk of investing in the sector. Belite Bio, however, a recently IPO'd company, has shown promising gains in its share price and has two Phase 3 studies underway for its lead candidate targeting eye diseases. Tinlarebant is an orally available therapy targeting Stargardt disease and Geographic Atrophy. The latter market could be worth over $10bn.

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Fitzgerald & Co. Yi Chen - HC Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference Call. At this time, all attendees are in a listen-only mode.

Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the three months ended June 30, 2023 and provided a general business update.

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it will host a live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to discuss the Company's financial results for the second quarter ended June 30, 2023, and provide a general business update.

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that, in its pivotal Phase 3 “PHOENIX” trial for subjects with GA, the first subject has been dosed at the Retina Associates of Southern California, a clinical trial site in the United States.

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that enrollment of its pivotal global Phase 3 “DRAGON” trial for patients with Stargardt Disease (STGD1) has completed. Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Investors, seeing the 52-week low, saw a bargain in Belite Bio. The company doesn't have any revenue, but it has a promising eye disease therapy.

Why Shares of Belite Bio Soared This Week

BLTE works with retinal disease patients. Their lead asset has positive phase 1 data. Their cash position and trial patient population are two worries.

Belite Bio: Undercovered Eye Disease Company With Early Data

Clearpoint Neuro Inc

Cooper Companies

iRhythm Technologies

STAAR Surgical

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Set To Fly In Q2

Belite Bio is a clinical-stage biopharmaceutical company focusing on rare eye diseases and other metabolic disorders. In the first quarter, the company said it had only $37.8 million in cash.

Why Shares of Belite Bio Are Slumping Wednesday

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, and warrants to purchase 2,000,000 ordinary shares represented by ADSs, at a public offering price of $15.00 per ADS and accompanying warrant. The warrants will be exercisable immediately, will expire five years from the date of issuance and will have an exercise price of $18.00 per ADS. The gross proceeds of the offering to the Company are expected to be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Belite Bio, and excluding the exercise of any warrants. All of the securities in the offering are to be sold by Belite Bio. The closing of the offering is expected to occur on or about June 2, 2023, subject to the satisfaction of customary closing conditions.

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares, and warrants to purchase ordinary shares represented by ADSs. All of the securities in the offering are to be sold by Belite Bio. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

Belite Bio, Inc (NASDAQ:BLTE ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald & Co. Timothy Lugo - William Blair & Company LLC Yi Chen - H.C. Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Yuan Zhi - B.

Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2023 and provided a general business update.

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a live webcast on Thursday, May 11, 2023, at 8:00 a.m. Eastern Time to discuss the Company's financial results for the first quarter ended March 31, 2023, and provide a general business update. The financial results will be issued in a press release on Wednesday, May 10, 2023.

News for Belite Bio Inc Stock (BLTE)